JP6315848B2 - Ｍｅｋ／ｐｉ３ｋ二重阻害剤および該阻害剤を使用する治療方法 - Google Patents

Ｍｅｋ／ｐｉ３ｋ二重阻害剤および該阻害剤を使用する治療方法 Download PDF

Info

Publication number
JP6315848B2
JP6315848B2 JP2016501365A JP2016501365A JP6315848B2 JP 6315848 B2 JP6315848 B2 JP 6315848B2 JP 2016501365 A JP2016501365 A JP 2016501365A JP 2016501365 A JP2016501365 A JP 2016501365A JP 6315848 B2 JP6315848 B2 JP 6315848B2
Authority
JP
Japan
Prior art keywords
cancer
alkyl
compound according
halo
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016501365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516702A5 (enExample
JP2016516702A (ja
Inventor
ロス，ブライアン，ディー．
ドルト，マルシャン ヴァン
ドルト，マルシャン ヴァン
ホワイトヘッド，クリストファー
Original Assignee
ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン
ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン, ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン filed Critical ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン
Publication of JP2016516702A publication Critical patent/JP2016516702A/ja
Publication of JP2016516702A5 publication Critical patent/JP2016516702A5/ja
Application granted granted Critical
Publication of JP6315848B2 publication Critical patent/JP6315848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016501365A 2013-03-13 2014-03-12 Ｍｅｋ／ｐｉ３ｋ二重阻害剤および該阻害剤を使用する治療方法 Active JP6315848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779462P 2013-03-13 2013-03-13
US61/779,462 2013-03-13
PCT/US2014/023860 WO2014164942A1 (en) 2013-03-13 2014-03-12 Dual mek/pi3k inhibitors and therapeutic methods using the same

Publications (3)

Publication Number Publication Date
JP2016516702A JP2016516702A (ja) 2016-06-09
JP2016516702A5 JP2016516702A5 (enExample) 2018-04-12
JP6315848B2 true JP6315848B2 (ja) 2018-04-25

Family

ID=51659015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501365A Active JP6315848B2 (ja) 2013-03-13 2014-03-12 Ｍｅｋ／ｐｉ３ｋ二重阻害剤および該阻害剤を使用する治療方法

Country Status (6)

Country Link
US (1) US9611258B2 (enExample)
EP (1) EP2968345B1 (enExample)
JP (1) JP6315848B2 (enExample)
CN (1) CN105358156A (enExample)
CA (1) CA2901613C (enExample)
WO (1) WO2014164942A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
CN108884159A (zh) 2015-11-07 2018-11-23 茂体外尔公司 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
JP2019519593A (ja) * 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
EP3551226A1 (en) 2016-12-12 2019-10-16 MultiVir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
AU2018316175B2 (en) * 2017-08-11 2023-02-23 The Regents Of The University Of Michigan Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021142144A1 (en) * 2020-01-10 2021-07-15 Immuneering Corporation Mek inhibitors and therapeutic uses thereof
CN111135309B (zh) * 2020-01-15 2023-04-28 重庆大学 一种核壳结构的替拉扎明药物载体及其制备方法和应用
AR121078A1 (es) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
MX2024008462A (es) * 2022-01-06 2024-09-06 Immuneering Corp Inhibidores de inmunooncología mek y usos terapéuticos de estos.
WO2024102859A1 (en) * 2022-11-09 2024-05-16 Immuneering Corporation Mek immune oncology inhibitors and therapeutic uses thereof
WO2025010287A2 (en) * 2023-07-03 2025-01-09 Immuneering Corporation Mek immune oncology inhibitors and therapeutic uses thereof
WO2025114495A1 (en) * 2023-11-28 2025-06-05 Universität Basel Pi3k inhibitors and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153817A0 (en) * 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
WO2008032060A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
EP2172198B1 (en) 2007-07-20 2014-04-16 Chugai Seiyaku Kabushiki Kaisha p27 PROTEIN INDUCER
EP2276750A2 (en) * 2008-03-27 2011-01-26 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
KR20110028651A (ko) * 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
JP5766177B2 (ja) 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US20110166191A1 (en) * 2010-01-07 2011-07-07 Shijun Zhang 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer
GB201007227D0 (en) * 2010-04-30 2010-06-16 Univ Basel Piperazinotriazines
EP2651442B1 (en) * 2010-12-14 2020-04-22 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer

Also Published As

Publication number Publication date
EP2968345A4 (en) 2016-08-17
US20160002212A1 (en) 2016-01-07
EP2968345A1 (en) 2016-01-20
EP2968345B1 (en) 2017-12-13
CA2901613C (en) 2020-10-20
WO2014164942A1 (en) 2014-10-09
JP2016516702A (ja) 2016-06-09
CN105358156A (zh) 2016-02-24
CA2901613A1 (en) 2014-10-09
US9611258B2 (en) 2017-04-04

Similar Documents

Publication Publication Date Title
JP6315848B2 (ja) Ｍｅｋ／ｐｉ３ｋ二重阻害剤および該阻害剤を使用する治療方法
US10196405B2 (en) Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors
AU2021202619B2 (en) Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same
CN115175679A (zh) 治疗雌激素受体相关疾病的方法
WO2014031487A1 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
EP3617195B1 (en) Novel tetrahydronaphthyl urea derivatives as inhibitors of tropomyosin receptor kinase a for the treatment of pain
US7371875B2 (en) Cytotoxic agents and methods of use
WO2011159685A2 (en) Inhibition of wdr5 interaction with its binding partners and therapeutic methods
CN113993519A (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
KR20210015833A (ko) 암 줄기 세포를 표적화하는 암 치료
US9175001B2 (en) [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
CN115260107B (zh) 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用
JP2025535801A (ja) Ｅｐｈａ２標的化剤及びその使用
AU2015228385A1 (en) Compounds for eradicating or inhibiting proliferation of cancer stem cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171207

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180320

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180326

R150 Certificate of patent or registration of utility model

Ref document number: 6315848

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250